JP2005530735A - 癌の処置のための併用療法 - Google Patents

癌の処置のための併用療法 Download PDF

Info

Publication number
JP2005530735A
JP2005530735A JP2003585723A JP2003585723A JP2005530735A JP 2005530735 A JP2005530735 A JP 2005530735A JP 2003585723 A JP2003585723 A JP 2003585723A JP 2003585723 A JP2003585723 A JP 2003585723A JP 2005530735 A JP2005530735 A JP 2005530735A
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
warm
effective amount
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003585723A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005530735A5 (enExample
Inventor
リャン，アンダーソン・ジョーゼフ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0208680A external-priority patent/GB0208680D0/en
Priority claimed from GB0218388A external-priority patent/GB0218388D0/en
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2005530735A publication Critical patent/JP2005530735A/ja
Publication of JP2005530735A5 publication Critical patent/JP2005530735A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
JP2003585723A 2002-04-16 2003-04-14 癌の処置のための併用療法 Pending JP2005530735A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0208680A GB0208680D0 (en) 2002-04-16 2002-04-16 Combination therapy
GB0218388A GB0218388D0 (en) 2002-08-08 2002-08-08 Combination therapy
PCT/GB2003/001617 WO2003088971A1 (en) 2002-04-16 2003-04-14 Combination therapy for the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2005530735A true JP2005530735A (ja) 2005-10-13
JP2005530735A5 JP2005530735A5 (enExample) 2006-05-11

Family

ID=29252451

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003585723A Pending JP2005530735A (ja) 2002-04-16 2003-04-14 癌の処置のための併用療法

Country Status (16)

Country Link
US (1) US20050215530A1 (enExample)
EP (1) EP1496909B1 (enExample)
JP (1) JP2005530735A (enExample)
KR (1) KR20040103964A (enExample)
CN (1) CN100352441C (enExample)
AT (1) ATE353650T1 (enExample)
AU (1) AU2003216558B2 (enExample)
BR (1) BR0309226A (enExample)
CA (1) CA2482591A1 (enExample)
DE (1) DE60311788T2 (enExample)
ES (1) ES2280735T3 (enExample)
IL (1) IL164564A0 (enExample)
MX (1) MXPA04010166A (enExample)
NO (1) NO20044498L (enExample)
NZ (1) NZ535739A (enExample)
WO (1) WO2003088971A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
JP2006527753A (ja) * 2003-06-18 2006-12-07 アンギオジェン・ファーマシューティカルズ・リミテッド 結腸直腸癌などの治療のための、血管損傷効果を有する、５−ｆｕ、ｃｐｔ−１１または５−ｆｕおよびｃｐｔ−１１と組み合わせたｚｄ６１２６を含んでなる組成物
ES2372694T3 (es) * 2003-10-15 2012-01-25 OSI Pharmaceuticals, LLC Inhibidores de tirosina cinasa de imidazo[1,5-a]pirazina.
MXPA06011423A (es) 2004-04-02 2007-01-23 Osi Pharm Inc Inhibidores de proteina cinasa heterobiciclica sustituida en el anillo 6,6-biciclico.
BRPI0511754A (pt) * 2004-06-03 2008-01-02 Smithkline Beechman Cork Ltd uso de um composto ou sais ou solvatos do mesmo
WO2005117916A1 (en) 2004-06-03 2005-12-15 F. Hoffmann-La Roche Ag Treatment with cisplatin and an egfr-inhibitor
US20060084666A1 (en) * 2004-10-18 2006-04-20 Harari Paul M Combined treatment with radiation and an epidermal growth factor receptor kinase inhibitor
FR2886151B1 (fr) * 2005-05-31 2007-09-07 Mayoly Spindler Soc Par Action Utilisation de la colchicine pour la preparation d'un medicament destine a la prevention et/ou au traitement de l'endometriose
US8575164B2 (en) * 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
EP2250173A1 (en) * 2008-01-18 2010-11-17 OSI Pharmaceuticals, Inc. Imidazopyrazinol derivatives for the treatment of cancers
ES2396613T3 (es) * 2008-05-19 2013-02-22 OSI Pharmaceuticals, LLC Imidazopirazinas e imidazotriazinas sustituidas
JP2012520893A (ja) 2009-03-18 2012-09-10 オーエスアイ・ファーマシューティカルズ，エルエルシー Ｅｇｆｒ阻害薬及びｉｇｆ−１ｒ阻害剤の投与を含む組み合わせ癌治療
EP2421837A1 (en) 2009-04-20 2012-02-29 OSI Pharmaceuticals, LLC Preparation of c-pyrazine-methylamines
WO2010129740A1 (en) * 2009-05-07 2010-11-11 Osi Pharmaceuticals, Inc. Use of osi-906 for treating adrenocortical carcinoma
WO2012129145A1 (en) 2011-03-18 2012-09-27 OSI Pharmaceuticals, LLC Nscle combination therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9714249D0 (en) * 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
EE200200565A (et) * 2000-03-31 2004-06-15 Angiogene Pharmaceuticals Ltd. Vaskulaarse kahjustava toimega kombinatsioonravi
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy

Also Published As

Publication number Publication date
AU2003216558A1 (en) 2003-11-03
HK1071310A1 (en) 2005-07-15
BR0309226A (pt) 2005-02-09
EP1496909A1 (en) 2005-01-19
NO20044498L (no) 2004-11-04
AU2003216558B2 (en) 2008-05-29
DE60311788T2 (de) 2007-11-22
US20050215530A1 (en) 2005-09-29
MXPA04010166A (es) 2005-02-03
CN100352441C (zh) 2007-12-05
ES2280735T3 (es) 2007-09-16
WO2003088971A1 (en) 2003-10-30
EP1496909B1 (en) 2007-02-14
IL164564A0 (en) 2005-12-18
NZ535739A (en) 2008-01-31
CA2482591A1 (en) 2003-10-30
DE60311788D1 (de) 2007-03-29
CN1658880A (zh) 2005-08-24
ATE353650T1 (de) 2007-03-15
KR20040103964A (ko) 2004-12-09

Similar Documents

Publication Publication Date Title
US20100130493A1 (en) Combination of vegf receptor tyrosine kinase inhibitors for treatment of cancer
CN100352441C (zh) 用于治疗肿瘤的zd6126和zd1839的联合药物
US20100179142A1 (en) Cancer Combination Therapy Comprising AZD2171 and ZD1839
US9943537B2 (en) Antitumor agent and antitumor effect enhancer
EP1651227B1 (en) Pharmaceutical compositions comprising azd 2171 and zd 6126 and uses thereof
KR20080031029A (ko) Ａｚｄ2171 및 젬시타빈에 의한 암의 병용 요법
HK1071310B (en) Combination therapy for the treatment of cancer
AU2003252976B2 (en) Combination of VEGF receptor tyrosine kinase inhibitors for treatment of cancer
HK1089384B (en) Pharmaceutical compositions comprising azd 2171 and zd 6126 and uses thereof
HK1089667B (en) Cancer combination therapy comprising azd2171 and zd1839

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060313

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090728

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20091222